VOL. XCIV, NO. 247

★ WIDE MOAT STOCKS COMPARISON ★

NO ADVICE

Friday, January 2, 2026

Stock Comparison

AstraZeneca PLC vs Corteva, Inc.

Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.

AstraZeneca PLC

AZN · London Stock Exchange

Market cap (USD)
Gross margin (TTM)
Operating margin (TTM)
Net margin (TTM)
SectorHealthcare
Industry
CountryGB
Data as of2026-01-02
Moat score
71/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into AstraZeneca PLC's moat claims, evidence, and risks.

View AZN analysis

Corteva, Inc.

CTVA · New York Stock Exchange

Market cap (USD)$45.6B
Gross margin (TTM)46.1%
Operating margin (TTM)15.3%
Net margin (TTM)9.2%
SectorMaterials
IndustryAgricultural Inputs
CountryUS
Data as of2025-12-28
Moat score
60/ 100

Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.

Full stock profile

Dive deeper into Corteva, Inc.'s moat claims, evidence, and risks.

View CTVA analysis

Comparison highlights

  • Moat score gap: AstraZeneca PLC leads (71 / 100 vs 60 / 100 for Corteva, Inc.).
  • Segment focus: AstraZeneca PLC has 6 segments (41% in Oncology); Corteva, Inc. has 2 segments (56.5% in Seed).
  • Primary market structure: Oligopoly vs Oligopoly. Pricing power: Strong vs Moderate.
  • Moat breadth: AstraZeneca PLC has 4 moat types across 3 domains; Corteva, Inc. has 4 across 3.

Primary market context

AstraZeneca PLC

Oncology

Market

Innovator oncology therapeutics (branded prescription medicines)

Geography

Global

Customer

Hospitals, oncology clinics, payers

Role

Innovator biopharmaceutical company

Revenue share

41%

Corteva, Inc.

Seed

Market

Commercial agricultural seeds and traits (corn, soybean, and other crops)

Geography

Global

Customer

Farmers via agricultural retailers/dealers and distributors

Role

Seed genetics/trait developer + branded seed seller (OEM)

Revenue share

56.5%

Side-by-side metrics

AstraZeneca PLC
Corteva, Inc.
Ticker / Exchange
AZN - London Stock Exchange
CTVA - New York Stock Exchange
Market cap (USD)
n/a
$45.6B
Gross margin (TTM)
n/a
46.1%
Operating margin (TTM)
n/a
15.3%
Net margin (TTM)
n/a
9.2%
Sector
Healthcare
Materials
Industry
n/a
Agricultural Inputs
HQ country
GB
US
Primary segment
Oncology
Seed
Market structure
Oligopoly
Oligopoly
Market share
n/a
n/a
HHI estimate
n/a
n/a
Pricing power
Strong
Moderate
Moat score
71 / 100
60 / 100
Moat domains
Legal, Supply, Demand
Legal, Supply, Demand
Last update
2026-01-02
2025-12-28

Moat coverage

Shared moat types

IP Choke Point

AstraZeneca PLC strengths

Regulated Standards PipeCapex Knowhow ScaleBrand Trust

Corteva, Inc. strengths

Learning Curve YieldSuite BundlingOperational Excellence

Segment mix

AstraZeneca PLC segments

Full profile >

Oncology

Oligopoly

41%

Cardiovascular, Renal and Metabolism (CVRM)

Competitive

23%

Respiratory & Immunology (R&I)

Oligopoly

15%

Vaccines & Immune Therapies (V&I)

Oligopoly

3%

Rare Disease

Oligopoly

16%

Other Medicines

Competitive

2%

Corteva, Inc. segments

Full profile >

Seed

Oligopoly

56.5%

Crop Protection

Oligopoly

43.5%

Want the full wide moat stocks list?

Browse the full ranking of wide moat stocks, updated with moat scores and segment context.

View the moat stocks list

Curation & Accuracy

This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).

Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.